Edition:
United Kingdom

Zimmer Biomet Holdings Inc (ZBH.N)

ZBH.N on New York Stock Exchange

124.40USD
19 Oct 2018
Change (% chg)

$-1.92 (-1.52%)
Prev Close
$126.32
Open
$126.55
Day's High
$127.34
Day's Low
$123.81
Volume
313,157
Avg. Vol
247,103
52-wk High
$133.99
52-wk Low
$104.28

Summary

Name Age Since Current Position

Larry Glasscock

69 2013 Independent Non-Executive Chairman of the Board

Bryan Hanson

51 2017 President, Chief Executive Officer, Director

Daniel Florin

53 2018 Chief Financial Officer, Executive Vice President

Robert Delps

48 2017 President, Americas

Sang Yi

55 2015 President, Asia Pacific

Chad Phipps

46 2007 Senior Vice President, General Counsel, Secretary

Coleman Lannum

51 2018 Senior Vice President - Investor Relations

Tony Collins

49 2015 Chief Accounting Officer, Vice President, Corporate Controller

Derek Davis

2018 Vice President of Investor Relations

Aure Bruneau

43 2017 Group President, Spine, CMF, Thoracic and Surgery Assisting Technology

David Nolan

52 2015 Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing

Daniel Williamson

52 2015 Group President, Joint Reconstruction

Maria Hilado

53 2018 Director

Syed Jafry

2018 Director

Christopher Begley

65 2012 Independent Director

Betsy Bernard

62 2009 Independent Director

Gail Boudreaux

57 2012 Independent Director

Michael Farrell

45 2014 Independent Director

Robert Hagemann

61 2008 Independent Director

Arthur Higgins

62 2007 Independent Director

Michael Michelson

66 2015 Independent Director

Biographies

Name Description

Larry Glasscock

Mr. Larry C. Glasscock is Independent Non-Executive Chairman of the Board of the Company. Chairman of WellPoint, Inc. (now Anthem, Inc.) from 2005 until 2010. Mr. Glasscock also served as President and Chief Executive Officer of WellPoint, Inc. from 2004 to 2007. Mr. Glasscock served as Chairman, President and Chief Executive Officer of Anthem, Inc. from 2003 to 2004 and served as President and Chief Executive Officer of Anthem, Inc. from 2001 to 2003. Mr. Glasscock earned a B.B.A. from Cleveland State University. He also completed the Commercial Bank Management Program at Columbia University.

Bryan Hanson

Mr. Bryan C. Hanson is President, Chief Executive Officer, Director of the Company. Previously, Mr. Hanson served as Executive Vice President and President, Minimally Invasive Therapies Group of Medtronic plc from January 2015 until joining Zimmer Biomet. Prior to that, he was Senior Vice President and Group President, Covidien of Covidien plc from October 2014 to January 2015; Senior Vice President and Group President, Medical Devices and United States of Covidien from October 2013 to September 2014; Senior Vice President and Group President of Covidien for the Surgical Solutions business from July 2011 to October 2013; and President of Covidien’s Energy-based Devices business from July 2006 to June 2011. Mr. Hanson held several other positions of increasing responsibility in sales, marketing and general management with Covidien from October 1992 to July 2006.

Daniel Florin

Mr. Daniel P. Florin is Chief Financial Officer, Executive Vice President of the Company. Prior to that appointment, he served as Senior Vice President and Chief Financial Officer from June 2015 to February 2018. In addition, he served as Interim Chief Executive Officer from July 2017 to December 2017. Prior to the Biomet merger, Mr. Florin served as Senior Vice President and Chief Financial Officer of Biomet from June 2007 to June 2015. Before joining Biomet, he served as Vice President and Corporate Controller of Boston Scientific Corporation from 2001 through May 2007. Prior to that, Mr. Florin served in financial leadership positions within Boston Scientific Corporation and its various business units. Before joining Boston Scientific Corporation, Mr. Florin worked for C.R. Bard from October 1990 through June 1995.

Robert Delps

Mr. Robert D. Delps is President, Americas of the Company. He is responsible for the Company’s sales and management of the direct and indirect sales channels in the Americas region, including the United States, Canada and Latin America. He served as Vice President, U.S. Sales from June 2015 until assuming his current role. Mr. Delp previously served in commercial Vice President roles with Biomet from October 2007 until June 2015. Prior to those appointments, Mr. Delp held numerous positions within the musculoskeletal healthcare field, where he began his career in 1995.

Sang Yi

Mr. Sang Yi is President, Asia Pacific of the Company. He is responsible for the sales, marketing and distribution of products in the Asia Pacific region. Mr. Yi joined the Company in March 2013 as Senior Vice President, Asia Pacific. Previously, he served as Vice President and General Manager of St. Jude Medical for Asia Pacific and Australia from 2005 to 2013. Prior to that, Mr. Yi held several leadership positions over a ten-year period with Boston Scientific Corporation, ultimately serving as Vice President for North Asia.

Chad Phipps

Mr. Chad F. Phipps is Senior Vice President, General Counsel, Secretary of the Company. He has global responsibility for the Company’s Legal Affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees the Company’s Government Affairs, Corporate Communication and Public Relations activities. Previously, Mr. Phipps served as Associate General Counsel and Corporate Secretary from December 2005 to May 2007. He joined the Company in September 2003 as Associate Counsel and Assistant Secretary. Prior to joining the Company, he served as Vice President and General Counsel of L&N Sales and Marketing, Inc. in Pennsylvania and he practiced law with the firm of Morgan, Lewis & Bockius in Philadelphia, focusing on corporate and securities law, mergers and acquisitions and financial transactions.

Coleman Lannum

Mr. Coleman N. Lannum is Senior Vice President - Investor Relations of the Company. Mr. Lannum joins Zimmer Biomet with more than 15 years of Investor Relations (IR) experience in the healthcare industry. Most recently, he served as Senior Vice President of Investor Strategy and Investor Relations Officer for Mallinckrodt Pharmaceuticals, where he consulted with executive management and the Board of Directors regarding the Company's acquisitions, strategic direction and shareholder value optimization. Prior to joiningMallinckrodtin 2015, Mr. Lannum led IR at Covidien and Tyco Healthcare for nine years. As Vice President and Investor Relations Officer, he designed Covidien's IR program, oversaw the largest-ever healthcare Initial Public Offering and led the IR effort through the company's merger with Medtronic in 2015. Mr. Lannum's leadership at Covidien andMallinckrodthas been recognized with numerous best-in-class honors, including an unprecedented five consecutive awards by IR Magazine for both Best US Investor Relations Officer - Large Cap and Grand Prix - Best Overall Investor Relations from 2011 through 2015.

Tony Collins

Mr. Tony W. Collins is Chief Accounting Officer, Vice President, Corporate Controller of the Company. Prior to that, Mr. Collins served as Vice President, Finance for the Global Reconstructive Division and Global Operations organization. He joined the Company in 2010 as Vice President, Finance for the Global Reconstructive Division and U.S. Commercial organization. Previously, Mr. Collins held the position of Vice President, Finance and served as the chief financial officer of the Commercial segment of Oshkosh Corporation from 2007 to 2010. From 1997 to 2007, he was employed at Guidant Corporation and Boston Scientific Corporation, where he held a number of positions of increasing responsibility, including Finance Director and chief financial officer of the Guidant Japan organization, Global Director of Operations Finance and Director of Strategic Planning.

Derek Davis

Aure Bruneau

Mr. Aure Bruneau is Group President, Spine, CMF, Thoracic and Surgery Assisting Technology of the company. Prior to that, Mr. Bruneau served as Vice President and General Manager with global responsibility for the Company’s Craniomaxillofacial and Thoracic businesses beginning in June 2015. He also led the integration of the Robotics business until assuming his current role. Previously, Mr. Bruneau served in Vice President roles of increasing responsibility in marketing, business development and general management at Biomet from September 2008 until June 2015. Prior to joining Biomet, Mr. Bruneau held numerous positions with Sofamor Danek Group and Medtronic over a 12-year period.

David Nolan

Mr. David A. Nolan Jr. is Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing of the Company. He has responsibility for the Company’s Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions businesses. He joined the Company in November 2012 as Senior Vice President, Sales. From January 2014 to June 2015, he served as Senior Vice President, Sales and Advanced Solutions. Prior to joining the Company, Mr. Nolan served as President, Biomet Sports Medicine, Extremities and Trauma from 2011 to 2012 and as President, Biomet Sports Medicine from 2001 to 2011. He joined Biomet in 1996.

Daniel Williamson

Mr. Daniel E. Williamson is Group President, Joint Reconstruction of the Company. Prior to the Biomet merger, he served as Senior Vice President, Biomet and President, Global Reconstructive Joints from February 2014 to June 2015. Prior to that, Mr. Williamson served as Biomet’s Vice President and General Manager, Global Bone Cement and Biomaterials Research from September 2011 to February 2014, and as Corporate Vice President, Global Biologics and Biomaterials from May 2006 to September 2011. Mr. Williamson previously served as Biomet’s Vice President, Business Development from December 2003 to May 2006. He began his career with Biomet in 1990 as a Product Development Engineer.

Maria Hilado

Ms. Maria Teresa Hilado is Director of the Company. Ms. Hilado brings more than 30 years of financial and leadership experience to Zimmer Biomet. Most recently, she served as Executive Vice President and Chief Financial Officer of Allergan PLC, a global pharmaceutical company, fromDecember 2014until her retirement inFebruary 2018. Prior to joining Allergan PLC, Ms. Hilado held the role of Senior Vice President, Finance and Treasurer of PepsiCo Inc. from 2009 to 2014. She previously served as Vice President and Treasurer for Schering-Plough Corp. and spent more than 17 years with General Motors Company in leadership roles of increasing responsibility.

Syed Jafry

Mr. Syed Jafry is Director of the Company. Mr. Jafry has more than 30 years of global operations and management experience in healthcare, infrastructure, energy and chemical industries. He currently serves as Senior Vice President and President,Asia Pacific, EMEA and Emerging Markets of Thermo Fisher Scientific Inc., a global leader in serving science, supporting customers in pharmaceutical, healthcare, diagnostics and research markets. He joined Thermo Fisher Scientific Inc. inMarch 2005and served in numerous P&L management roles of increasing responsibility prior to being appointed to his current position. Mr. Jafry began his career at Glaxo Pharmaceuticals inLondon. Prior to joining Thermo Fisher Scientific, he served for 18 years at General Electric, where he held commercial, product management and general management roles in the U.S.,Netherlands,SwitzerlandandChina, with his role as President of GE Sensing Asia. He earned a Bachelor of Science in Mechanical Engineering from Lahore University in Pakistan, a Master of Science in Mechanical Engineering from the University of Massachusetts and a Master's Certificate in Marketing and Management from Harvard University Extension School.

Christopher Begley

Mr. Christopher B. Begley is Independent Director of the Company. Executive Chairman of the Board of Hospira, Inc. from May 2007 until his retirement in January 2012. Mr. Begley also served as Chief Executive Officer from April 30, 2004, when Hospira was spun off from Abbott Laboratories, to March 2011. Prior to that, Mr. Begley served in various positions with Abbott between 1986 and 2004, most recently as Senior Vice President of Abbott’s Hospital Products division. He earned a bachelor’s degree from Western Illinois University and an MBA from Northern Illinois University.

Betsy Bernard

Ms. Betsy J. Bernard is Independent Director of the Company. President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University’s Sloan Fellowship Program.

Gail Boudreaux

Ms. Gail Koziara Boudreaux is Independent Director of the Company. President and Chief Executive Officer, Anthem, Inc. since November 2017. Previously, Ms. Boudreaux served as Chief Executive Officer and Founder, GKB Global Health, LLC from 2015 to November 2017. Prior to that, she served as Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014 and Executive Vice President of UnitedHealth Group from May 2008 to February 2015. From 2005 to 2008, Ms. Boudreaux served as Executive Vice President, External Operations for Health Care Services Corporation (“HCSC”), and prior to that served as President of Blue Cross and Blue Shield of Illinois, a division of HCSC. Before joining HCSC, Ms. Boudreaux held various positions at Aetna, including Senior Vice President, Aetna Group Insurance. Ms. Boudreaux earned a bachelor’s degree in psychology from Dartmouth College and an MBA from Columbia Business School.

Michael Farrell

Mr. Michael J. Farrell is Independent Director of Zimmer Biomet Holdings, Inc. Chief Executive Officer of ResMed Inc. since March 2013. Prior to that appointment, Mr. Farrell served as President – Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company and BHP Billiton. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management.

Robert Hagemann

Mr. Robert A. Hagemann is Independent Director of Zimmer Biomet Holdings, Inc. He served as the Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics’ former parent company, Corning Incorporated, in 1992, and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University.

Arthur Higgins

Mr. Arthur J. Higgins is Independent Director of Zimmer Biomet Holdings, Inc. He is President, Chief Executive Officer and a member of the board of directors of Depomed, Inc. since March 2017. Consultant, Blackstone Healthcare Partners of The Blackstone Group since June 2010. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry.

Michael Michelson

Mr. Michael W. Michelson is Independent Directorof the Company. Mr. Michelson served as Senior Advisory Partner, KKR Management LLC, a private equity investment manager and the general partner of KKR & Co. L.P., since January 2018. Previously, Member, KKR Management LLC since October 2009. Before that, Mr. Michelson was a member of the limited liability company that served as the general partner of Kohlberg Kravis Roberts & Co. L.P. since 1996. He joined KKR in 1981. Mr. Michelson has played a significant role in the development of KKR’s portfolio companies. He began his professional career with the law firm of Latham & Watkins in Los Angeles, where he was involved in a broad corporate practice while specializing in management buyouts. He earned an A.B. from Harvard College and a J.D. from Harvard Law School.